NCT06734585View on ClinicalTrials.gov

Using Gilteritinib to Keep People With Acute Myeloid Leukemia Cancer-free After a Stem Cell Transplant

CompletedOBSERVATIONAL
Enrollment

114

Participants

Timeline

Start Date

January 9, 2025

Primary Completion Date

July 14, 2025

Study Completion Date

July 14, 2025

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Gilteritinib

tablet, oral

Trial Locations (18)

Unknown

AU61001, Melbourne

AU61002, Melbourne

BR55004, Fortaleza

BR55002, Porto Alegre

BR55001, São Paulo

BR55003, São Paulo

CN86003, Shanghai

CN86004, Suzhou

CN86001, Tianjin

HK852001, Hong Kong

KR82004, Busan

KR82005, Gwangju

KR82001, Seoul

KR82002, Seoul

KR82003, Seoul

TW88603, Taichung

TW88602, Tainan City

TW88601, Taipei

All Listed Sponsors
lead

Astellas Pharma Singapore Pte. Ltd.

INDUSTRY

NCT06734585 - Using Gilteritinib to Keep People With Acute Myeloid Leukemia Cancer-free After a Stem Cell Transplant | Biotech Hunter | Biotech Hunter